Jason Wild  Background: NAFLD is an increasingly prevalent disease worldwide and costs the United States alone $100M annually2. It has recently been renamed to metabolic associated fatty liver disease (MAFLD) and defines a spectrum of liver disease that range from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH)2,3. The pathogenesis…

Ethan Hardy Background: Metabolic dysfunction-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease (NAFLD), poses a significant global health challenge, affecting approximately 32.4% of the global population.1-4 Characterized by hepatic lipid accumulation and associated complications such as liver fibrosis and hepatocellular carcinoma, this condition underscores the need…

Glori Das Introduction: An estimated 25% of the global population suffers from Non-Alcoholic Fatty Liver Disease (NAFLD)1. NAFLD is a progressive condition characterized by hepatocyte lipid accumulation (HLA) and fibrosis in its more advanced stages. Multiple pathways controlled by noradrenergic (NAergic) signaling have been implicated in NAFLD pathogenesis2,3,4. The goal…